Madrigal Pharmaceuticals ...

NASDAQ: MDGL · Real-Time Price · USD
369.75
-1.62 (-0.44%)
At close: Aug 15, 2025, 3:59 PM
344.50
-6.83%
After-hours: Aug 15, 2025, 07:58 PM EDT

Madrigal Pharmaceuticals Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022 Q2 2022 Q1 2022 Q4 2021 Q3 2021 Q2 2021 Q1 2021
Period Ending Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021
Revenue
212.8M 137.25M 103.32M 62.17M 14.64M n/a 770K n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Cost of Revenue
9.44M 4.51M 3.44M 2.15M 903K 168K 142K 135K 126K 124K 129K 121K 110K 107K 106K 97K 89K 113K
Gross Profit
203.36M 132.74M 100.31M 60.02M 13.73M -168K -142K -135K -126K -124K -129K -121K -110K -107K -106K -97K -89K -113K
Operating Income
-47.2M -79.31M -67M -116.3M -162.54M -152.04M -117.18M -98.53M -86.45M -78.34M -85.3M -80.41M -70.27M -57.45M -64.6M -63.16M -61.74M -52.98M
Interest Income
8.23M 9.37M 11.08M 13.02M 14.22M 8.33M 8.95M 3.3M 3.55M 3.78M 1.08M 717K 323K 69K 52K 60K 91K 160K
Pretax Income
-42.28M -73.24M -59.42M -106.96M -151.97M -147.54M -112.19M -98.74M -85.8M -76.9M -85.91M -81.2M -70.73M -57.52M -64.55M -63.1M -61.65M -52.55M
Net Income
-42.28M -73.24M -59.42M -106.96M -151.97M -147.54M -112.19M -98.74M -85.8M -77.79M -87.59M -81.2M -71.51M -57.59M -64.55M -63.1M -61.65M -52.55M
Selling & General & Admin
196.86M 167.88M 141.22M 107.58M 105.45M 80.8M 46.54M 27.58M 17.84M 16.18M 14.56M 12.14M 11.77M 9.66M 11.71M 8.29M 10.11M 7.21M
Research & Development
53.7M 44.17M 25.65M 68.74M 70.82M 71.07M 70.5M 70.95M 68.61M 62.15M 70.74M 68.27M 58.5M 47.93M 52.89M 54.87M 51.63M 45.77M
Other Expenses
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 273K
Operating Expenses
250.56M 212.05M 167.31M 176.33M 176.27M 151.87M 117.03M 98.53M 86.45M 78.34M 85.3M 80.41M 70.27M 57.59M 64.6M 63.16M 61.74M 52.98M
Interest Expense
3.26M 3.3M 3.5M 3.68M 3.66M 3.84M 3.97M 3.5M 2.9M 2.34M 1.68M 1.5M 780K n/a n/a n/a n/a n/a
Selling & Marketing Expenses
n/a n/a -152.61M n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Cost & Expenses
260M 216.56M 170.32M 178.48M 177.18M 152.04M 117.18M 98.53M 86.45M 78.34M 85.3M 80.41M 70.27M 57.59M 64.6M 63.16M 61.74M 52.98M
Income Tax Expense
n/a n/a n/a n/a n/a n/a 98.19K -135K n/a 896K 1.68M n/a 780K 69K -106K n/a n/a -160K
Shares Outstanding (Basic)
22.21M 22.09M 21.27M 21.75M 21.4M 20M 19.76M 18.48M 18.31M 18.19M 17.24M 17.1M 17.1M 17.1M 17.07M 16.64M 16.57M 15.84M
Shares Outstanding (Diluted)
22.21M 22.09M 21.27M 21.75M 21.4M 20M 19.76M 18.48M 18.31M 18.19M 17.24M 17.1M 17.1M 17.1M 17.07M 16.64M 16.57M 15.84M
EPS (Basic)
-1.9 -3.32 -2.5 -4.92 -7.1 -7.38 -5.68 -5.34 -4.69 -4.28 -5.08 -4.84 -4.18 -3.37 -3.78 -3.79 -3.72 -3.32
EPS (Diluted)
-1.9 -3.32 -2.5 -4.92 -7.1 -7.38 -5.68 -5.34 -4.69 -4.28 -5.08 -4.84 -4.18 -3.37 -3.78 -3.79 -3.72 -3.32
EBITDA
-38.64M -69.56M -55.55M -102.99M -148.05M -143.53M -108.08M -95.1M -82.77M -74.44M -84.09M -79.57M -69.84M -57.41M -64.5M -63M -61.56M -52.87M
EBIT
-39.02M -69.94M -55.92M -103.28M -148.31M -143.7M -108.22M -95.24M -82.9M -74.56M -84.22M -79.69M -69.95M -57.52M -64.6M -63.1M -61.65M -52.98M
Depreciation & Amortization
377K 379K 363K 298K 267K 168K 142K 135K 126K 124K 129K 121K 110K 107K 106K 97K 89K 113K